Personalis (NASDAQ:PSNL) CEO Sells $219,397.18 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 19,909 shares of Personalis stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $11.02, for a total value of $219,397.18. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $2,600,565.72. The trade was a 7.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Price Performance

PSNL stock opened at $11.40 on Monday. The firm has a market capitalization of $1.19 billion, a PE ratio of -11.18 and a beta of 2.27. Personalis, Inc. has a twelve month low of $3.84 and a twelve month high of $11.85. The stock has a 50-day simple moving average of $6.86 and a two-hundred day simple moving average of $8.10.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.49 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. On average, equities research analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd boosted its stake in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares in the last quarter. Legal & General Group Plc purchased a new stake in Personalis in the second quarter worth approximately $30,000. International Assets Investment Management LLC purchased a new stake in Personalis in the fourth quarter worth approximately $31,000. BNP Paribas Financial Markets boosted its stake in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in shares of Personalis in the 1st quarter valued at $47,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on PSNL. Needham & Company LLC boosted their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research cut their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Finally, Morgan Stanley cut their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.